期刊文献+

CAG方案联合小剂量地西他滨治疗老年人中高危骨髓增生异常综合征效果观察

Effect of CAG regimen combined with with low-dose decitabine in the treatment of middle and high risk myelodysplastic syndromes in the elderly
原文传递
导出
摘要 目的探究治疗老年人中高危骨髓增生异常综合征使用CAG方案与小剂量地西他滨联合的临床疗效。方法选取2015年1月—2016年7月收治的老年人及中高危骨髓增生综合征的患者88例,随机分为对照组和观察组,各44例。对照组给予CAG方案治疗,观察组在对照组基础上给予地西他滨治疗,比较两组临床疗效及不良反应发生率。计数资料比较采用χ2检验,P<0.05为差异有统计学意义。结果观察组治疗总有效率高于观察组,不良反应发生率低于对照组(均P<0.05)。结论地西他滨联合CAG方案治疗老年人中高危骨髓增生异常综合征效果明显,药物不良反应发生率较低。
作者 袁本超
出处 《社区医学杂志》 2018年第8期45-46,共2页 Journal Of Community Medicine
  • 相关文献

参考文献5

二级参考文献42

  • 1Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J]. Blood, 2006, 108(2):419-425.
  • 2Cheson BD, Bennett JM, Kopecky I/J, eta/. Revised recommoendations of the International Working Group (IWG) for diagnosis, standardization of response criteria,treatment outcomes,and reporting standards for therapeutic traials in acute myeloid leukemia[J].J C/in Oncol, 2003, 21 (24):4642-4649.
  • 3Miller AB, Hoogstraten B, Staquet M, et a/. Reporting results of cancer treatment[J]. Cancer, 1981, 47(1), 207-214.
  • 4Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in rnyelodysplastic syndromes: Results of a phase ]II randomized study[J]. Cancer, 2006, 106(8):1794-1803.
  • 5Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomrized study of 3 schedules of low- dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J]. Blood, 2007, 109(1):52-57.
  • 6Cashen A, Schiller G, Larsen JS, et al. Phase II study of low-dose decitabine for the frist-line treatment of older patients with acute myeloid leukemia (AML)[J]. J Clin Oncol, 2010, 28(4):556-$61.
  • 7Yamada K, Furusawas S, Saito K, et a/. Concurrent use of granulocyte colony-stimulating factor with low- dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: apilot study[J]. Leukemia, 1995, 9(1 ):10-14.
  • 8Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines[J]. Clin Cancer Res, 2007, 131 (4):4225-4232.
  • 9wijermans PW, Lubbertm, Verhodf G, et a/, An epigenetic approach to the treatment of advanced MDS; the experience with the DNA dernethylating agent 5-aza-2'- deoxycytidine (decitabine) in 177 patients[J]. Ann Hematol, 2005, 84(Suppl 13):9-17.
  • 10Ferrara F. Conventional chemotherapy or hypomethylating agents for older patientts with acute myeloid leukemia[J]. Hematol Oncol, 2014, 32(1):1-9.

共引文献98

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部